In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

There have been cancer vaccines which have shown promising results in other types of tumors, but this is one of the first ... people with later stage kidney cancers have a high risk of their ...

"And after a median follow up of almost four years, none of the nine vaccinated patients has experienced a recurrence from their kidney cancer." Standard treatment for stage ... 1:06 PM UTC ...

At this stage, the cancer will typically ... early recognition guidance means that kidney cancer may not be immediately identified. "Twenty-one per cent of patients in our survey said they were ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...

Scientists are encouraged by findings that jab can eliminate tumour in patients with stage three or four kidney cancer ...

Cancer researchers are one step closer to developing ... In the meantime, Choueiri is involved in a mid-stage Merck-led trial, in which nearly 300 patients with kidney cancer are being given ...

Four in five cases of disease are diagnosed when patients have scans for unrelated conditions or in emergency departments, ...